Advertisement

Topics

Latest "OncoDNA" News Stories

18:29 EDT 17th June 2018 | BioPortfolio

Here are the most relevant search results for "OncoDNA" found in our extensive news archives from over 250 global news sources.

More Information about OncoDNA on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about OncoDNA for you to read. Along with our medical data and news we also list OncoDNA Clinical Trials, which are updated daily. BioPortfolio also has a large database of OncoDNA Companies for you to search.

Showing "OncoDNA" News Articles, all 4

Extremely Relevant

OncoDNA announces publication of peer-reviewed study in Oncotarget assessing the utility of its uniq

(Rapamycin Press) OncoDNA treatment recommendation followed in 60% of cases. 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA. 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival >12 months, compared to a typical average of no more than six months.


OncoDNA announces publication of peer-reviewed study in Oncotarget assessing the utility of its unique biomarker analysis and interpretation platform in clinical decision making

(Rapamycin Press) OncoDNA treatment recommendation followed in 60% of cases. 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA. 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival >12 months, compared to a typical average of no more than six months.

Relevant

OncoDNA announces screening collaboration with Kura Oncology

- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE NEWSWIRE) -- OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, is pleased to announce that it has signed a screening agreement with Ku...


Possibly Relevant

Bone Therapeutics SA strengthens Board with the appointment of Jean Stéphenne as Chairman

Regulated information Bone Therapeutics strengthens Board with the appointment of Jean Stéphenne as Chairman Jean Stéphenne brings extensive biotech and pharma experience Gosselies, Belgium, 20 February 2018, 6 pm CET - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone d...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks